

James Lomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3582422/publications.pdf>

Version: 2024-02-01

34
papers

916
citations

567281

15
h-index

501196

28
g-index

36
all docs

36
docs citations

36
times ranked

1219
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. <i>Health Policy and Planning</i> , 2022, 37, 45-54. | 2.7 | 8 |
| 2 | Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. <i>Pharmacoeconomics</i> , 2022, 40, 31-43. | 3.3 | 16 |
| 3 | The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. <i>Pharmacoeconomics</i> , 2022, 40, 233-239. | 3.3 | 4 |
| 4 | How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 557-572. | 2.1 | 5 |
| 5 | Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 793-802. | 2.1 | 3 |
| 6 | Valuing health outcomes: developing better defaults based on health opportunity costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 729-736. | 1.4 | 16 |
| 7 | A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 25-32. | 3.9 | 103 |
| 8 | Does public long-term care expenditure improve care-related quality of life of service users in England?. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2561-2581. | 1.7 | 5 |
| 9 | How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 885-903. | 2.1 | 16 |
| 10 | Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2021, , 1. | 2.1 | 10 |
| 11 | Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. <i>BMJ Open</i> , 2021, 11, e046417. | 1.9 | 11 |
| 12 | Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. <i>Value in Health</i> , 2020, 23, 1027-1033. | 0.3 | 10 |
| 13 | Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. <i>BMJ Global Health</i> , 2020, 5, e003006. | 4.7 | 14 |
| 14 | Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. <i>Pharmacoeconomics</i> , 2020, 38, 1319-1331. | 3.3 | 48 |
| 15 | Assessing the Impact of Health Care Expenditures on Mortality Using Cross-Country Data. <i>World Scientific Series in Global Healthcare Economics and Public Policy</i> , 2020, , 3-49. | 0.1 | 3 |
| 16 | Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations. <i>Pharmacoeconomics</i> , 2020, 38, 665-681. | 3.3 | 9 |
| 17 | Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. <i>Clinical Therapeutics</i> , 2020, 42, 44-59.e2. | 2.5 | 16 |
| 18 | Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. <i>BMJ Open</i> , 2020, 10, e036411. | 1.9 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. <i>Value in Health</i> , 2019, 22, 898-905. | 0.3 | 21 |
| 20 | Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. <i>Value in Health</i> , 2019, 22, 995-1002. | 0.3 | 45 |
| 21 | Accounting for Timing when Assessing Health-Related Policies. <i>Journal of Benefit-Cost Analysis</i> , 2019, 10, 73-105. | 1.2 | 17 |
| 22 | An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2019, 37, 631-643. | 3.3 | 33 |
| 23 | Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. <i>Pharmacoeconomics - Open</i> , 2018, 2, 403-413. | 1.8 | 7 |
| 24 | The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. <i>Health Economics (United Kingdom)</i> , 2017, 31, 50-53. | 10.7 | 107 |
| 25 | Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. <i>Value in Health</i> , 2018, 21, 266-275. | 0.3 | 58 |
| 26 | Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. <i>BMJ Global Health</i> , 2018, 3, e000964. | 4.7 | 181 |
| 27 | Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2459. | 2.6 | 12 |
| 28 | Using Mobile Health Gamification to Facilitate Cognitive Behavioral Therapy Skills Practice in Child Anxiety Treatment: Open Clinical Trial. <i>JMIR Serious Games</i> , 2018, 6, e9. | 3.1 | 65 |
| 29 | A Quasi-Monte-Carlo Comparison of Parametric and Semiparametric Regression Methods for Heavy-tailed and Non-normal Data: an Application to Healthcare Costs. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2016, 179, 951-974. | 1.1 | 25 |
| 30 | A pharmaco-economic approach to assessing the costs and benefits of air quality interventions that improve health: a case study. <i>BMJ Open</i> , 2016, 6, e010686. | 1.9 | 12 |
| 31 | The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 901-912. | 3.3 | 7 |
| 32 | Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 981-992. | 3.3 | 4 |
| 33 | Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution. <i>Health Economics (United Kingdom)</i> , 2015, 24, 1192-1212. | 1.7 | 52 |
| 34 | APPLYING BETA-TYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. <i>Journal of Applied Econometrics</i> , 2014, 29, 649-670. | 2.3 | 27 |